MDX-210 shows significant antitumor activity in prostate and kidney cancer patients May 22, 1998 No Comments
97% response rate for Rituxan + CHOP in small pilot trial in intermediate- or high-grade NHL May 21, 1998 No Comments
Favorable preliminary phase I/II trials results reported at ASCO for Titan's cancer vaccines May 21, 1998 No Comments
Neurocrine Biosciences initiates clinical-stage development of IL-4 fusion toxin May 19, 1998 No Comments
DAB389IL-7, a novel fusion protein for the specific elimination of IL-7 receptor-positive cells May 12, 1998 No Comments
RSS